Zimmer Biomet Rides On New Operational Plan Amid Several Woes
Zacks Investment Research | Dec 03, 2018 09:09PM ET
On Dec 3, we issued an updated research report on Zimmer Biomet Holdings Inc. (NYSE:ZBH) . While strategic acquisitions and planned operational execution buoy optimism on the stock, issues like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations adversely impacted the company’s sales. The company carries a Zacks Rank #3 (Hold).
In order to address several near-term challenges, management recently started to review its 2018 operating plan to clearly define its go-forward strategies in a number of key areas. In this regard, the company has identified several immediate opportunities to improve Zimmer Biomet’s operational execution.
First, the company has plans to continue with its efforts in completing its quality remediation work at the Warsaw North Campus. In this context, to support the quality compliance of its manufacturing network, Zimmer Biomet will consistently invest in developing a best-in-class quality management system.
Second, in order to revive accelerated sales recapture, the company aims to steadily focus on fully restoring the supply of certain key brands within knee, hip and SET categories.
Third, with respect to commercial strategy, Zimmer Biomet’s immediate priorities are to restore supply, engage with the sales channel and return to offense. In addition to sales recapture, the company will also target the significant quantity of commercial releases scheduled in 2018. Per the latest update, Zimmer Biomet is on track to have a complete product portfolio in the back half of 2019.
Also, the company is progressing well with its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application. Moreover, management has notified that Zimmer Biomet is ahead of its schedule to perform its first case in Australia.
This apart, improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its priority goals like quality remediation, supply recovery efforts and product launches, Zimmer Biomet is constantly reporting top-line figures within its S.E.T arm.
On the flip side, we are concerned about the escalating costs and expenses exerting considerable pressure on the company’s bottom line. Also, declining dental sales at CER is a drag. Negative currency movements persist to be a major headwind for the company.
Over the past three months, shares of this leading musculoskeletal healthcare company have underperformed the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.